Harnessing natural killer cell effector function against cancer
Harnessing natural killer cell effector function against cancer
Natural killer (NK) cells are cytotoxic innate lymphoid cells that participate in anti-tumour and anti-viral immune responses. Their ability to rapidly destroy abnormal cells and to enhance the anti-cancer function of dendritic cells, CD8+ T cells, and macrophages makes them an attractive target for immunotherapeutic strategies. The development of approaches that augment NK-cell activation against cancer is currently under intense preclinical and clinical research and strategies include chimeric antigen receptor NK cells, NK-cell engagers, cytokines, and immune checkpoint inhibitors. In this review, we highlight recent advances in NK-cell therapeutic development and discuss their potential to add to our armamentarium against cancer.
cancer, CAR-NK cells, chimeric antigen receptor (CAR), immunotherapy, natural killer cells (NK cells), NK-cell engagers
ltad031
Blunt, Matthew D.
b1109de3-6045-4bc3-bd77-6cf26504697d
Khakoo, Salim I.
6c16d2f5-ae80-4d9b-9100-6bfb34ad0273
2024
Blunt, Matthew D.
b1109de3-6045-4bc3-bd77-6cf26504697d
Khakoo, Salim I.
6c16d2f5-ae80-4d9b-9100-6bfb34ad0273
Blunt, Matthew D. and Khakoo, Salim I.
(2024)
Harnessing natural killer cell effector function against cancer.
Immunotherapy Advances, 4 (1), , [ltad031].
(doi:10.1093/immadv/ltad031).
Abstract
Natural killer (NK) cells are cytotoxic innate lymphoid cells that participate in anti-tumour and anti-viral immune responses. Their ability to rapidly destroy abnormal cells and to enhance the anti-cancer function of dendritic cells, CD8+ T cells, and macrophages makes them an attractive target for immunotherapeutic strategies. The development of approaches that augment NK-cell activation against cancer is currently under intense preclinical and clinical research and strategies include chimeric antigen receptor NK cells, NK-cell engagers, cytokines, and immune checkpoint inhibitors. In this review, we highlight recent advances in NK-cell therapeutic development and discuss their potential to add to our armamentarium against cancer.
Text
ltad031
- Version of Record
More information
Accepted/In Press date: 18 December 2023
e-pub ahead of print date: 21 December 2023
Published date: 2024
Additional Information:
© The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Immunology.
Publisher Copyright:
© The Author(s) 2023.
Keywords:
cancer, CAR-NK cells, chimeric antigen receptor (CAR), immunotherapy, natural killer cells (NK cells), NK-cell engagers
Identifiers
Local EPrints ID: 486235
URI: http://eprints.soton.ac.uk/id/eprint/486235
PURE UUID: 49f3e9ef-4f73-4ac2-b733-dbf11290afda
Catalogue record
Date deposited: 15 Jan 2024 17:44
Last modified: 20 Apr 2024 01:52
Export record
Altmetrics
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
